Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itraconazole's effect on HRS-8080 pharmacokinetics in healthy participants
NCT07229560Phase 1Completed
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
- Start
- Nov 2025
- Primary completion
- Dec 2025
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HRS-8080 in breast cancer, sponsored by Shandong Suncadia Medicine Co., Ltd. Primary endpoints: Maximum concentration at 11 days, Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration at 11 days and 1 more. Started Nov 2025; status: completed.
02
Drugs
HRS-8080
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07229560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07229560.